Veru is a biopharmaceutical company. Co.'s infectious disease clinical development program includes: COVID-19 patients at risk for acute respiratory distress syndrome; and Sabizabulin, a microtubule disruptor. Co.'s oncology clinical development program includes: breast cancer, which consist of Enobosarm, a selective androgen receptor and Sabizabulin, a microtubule disruptor; and prostate cancer, which include Sabizabulin, a microtubule disruptor, VERU-100, a GnRH antagonist depot and Zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist. Co.'s sexual health program include ENTADFI, for the treatment of benign prostatic hyperplasia. When considering the Veru Inc stock dividend history, we have taken known splits into account, such that the VERU dividend history is presented on a split-adjusted ("apples to apples") basis. Veru Inc dividend history is presented both in graphical/chart form, and as a VERU dividend history data table along the right-hand column.
|
VERU Stock Dividend HistoryThe VERU dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable VERU historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the VERU dividend history record. Also see the VERU stock dividend history data table along the right-hand column below. |
|
|
Buy (3.25 out of 4) 46th percentile
(ranked lower than approx. 54% of all stocks covered)
Analysts' Target Price: VERU Forecast Based on data provided by Zacks Investment Research via Quandl.com |